Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Latest Content

Akero to expand ongoing Phase IIa trial of AKR-001 for NASH

Akero Therapeutics is set to expand the ongoing Phase IIa BALANCED study of Fc-FGF21 fusion protein AKR-001 to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.

Gilead combination therapy for NASH misses Phase II primary goal

Top-line data reported by Gilead Sciences has revealed that the Phase II ATLAS clinical trial of cilofexor, firsocostat and selonsertib did not meet the primary endpoint in nonalcoholic steatohepatitis (NASH) patients with bridging fibrosis (F3) and compensated cirrhosis (F4).


Go Top